Eric Toth

Dr. Eric Toth

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in DNA Repair
Verified
Journal Article
Closed access
PLPaz J. Luncsford
Paz J. Luncsford
BMBrittney A. Manvilla
Brittney A. Manvilla
DPDimeka N. Patterson
Dimeka N. Patterson
SMShuja S. Malik
Shuja S. Malik
JJJin Jin
Jin Jin
ETEric Toth
Eric Toth

5 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMatthew C. Metcalf
Matthew C. Metcalf
BJBenjamin M. Janus
Benjamin M. Janus
RYRui Yin
Rui Yin
RWRuixue Wang
Ruixue Wang
JGJohnathan D. Guest
Johnathan D. Guest
GOGilad Ofek
Gilad Ofek
Hepatitis C virus (HCV) is a major global health burden as the leading causative agent of chronic liver disease and hepatocellular carcinoma. While the main antigenic target for HCV-neutralizing antibodies is the membrane-associated E1E2 surface glycoprotein, the development of effective vaccines has been hindered by complications in the biochemical preparation of soluble E1E2 ectodomains. Here, we present a cryo-EM structure of an engineered, secreted E1E2 ectodomain of genotype 1b in complex with neutralizing antibodies AR4A, HEPC74, and IGH520. Structural characterization of the E1 subunit and C-terminal regions of E2 reveal an overall architecture of E1E2 that concurs with that observed for non-engineered full-length E1E2. Analysis of the AR4A epitope within a region of E2 that bridges between the E2 core and E1 defines the structural basis for its broad neutralization. Our study presents the structure of an E1E2 complex liberated from membrane via a designed scaffold, one that maintains all essential structural features of native E1E2. The study advances the understanding of the E1E2 heterodimer structure, crucial for the rational design of secreted E1E2 antigens in vaccine development.

28 January 2016 in BMC Structural Biology
Verified
Journal Article
Open access
PDF file
LPLakshmi Swarna Mukhi Pidugu
Lakshmi Swarna Mukhi Pidugu
JMJ.C. Emmanuel Mbimba
J.C. Emmanuel Mbimba
MAMuqeet Ahmad
Muqeet Ahmad
EPEdwin Pozharski
Edwin Pozharski
ESEdward A. Sausville
Edward A. Sausville
ETEric Toth
Eric Toth
Multimeric naphthoquinones are redox-active compounds that exhibit antineoplastic, antiprotozoal, and antiviral activities. Due to their multimodal effect on perturbation of cellular oxidative state, these compounds hold great potential as therapeutic agents against highly proliferative neoplastic cells. In our previous work, we developed a series of novel dimeric naphthoquinones and showed that they were selectively cytotoxic to human acute myeloid leukemia (AML), breast and prostate cancer cell lines. We subsequently identified the oxidoreductase NAD(P)H dehydrogenase, quinone 1 (NQO1) as the major target of dimeric naphthoquinones and proposed a mechanism of action that entailed induction of a futile redox cycling. Here, for the first time, we describe a direct physical interaction between the bromohydroxy dimeric naphthoquinone E6a and NQO1. Moreover, our studies reveal an extensive binding interface between E6a and the isoalloxazine ring of the flavin adenine dinucleotide (FAD) cofactor of NQO1 in addition to interactions with protein side chains in the active site. We also present biochemical evidence that dimeric naphthoquinones affect the redox state of the FAD cofactor of NQO1. Comparison of the mode of binding of E6a with those of other chemotherapeutics reveals unique characteristics of the interaction that can be leveraged in future drug optimization efforts. The first structure of a dimeric naphthoquinone-NQO1 complex was reported, which can be used for design and synthesis of more potent next generation dimeric naphthoquinones to target NQO1 with higher affinity and specificity.

9 March 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
RWRuixue Wang
Ruixue Wang
SSSaori Suzuki
Saori Suzuki
JGJohnathan Guest
Johnathan Guest
BHBrigitte Heller
Brigitte Heller
MAMaricar Almeda
Maricar Almeda
TFThomas Fuerst
Thomas Fuerst
Significance: Hepatitis C virus chronically infects approximately 1% of the world’s population, making an effective vaccine for hepatitis C virus a major unmet public health need. The membrane-associated E1E2 envelope glycoprotein has been used in clinical studies as a vaccine candidate. However, limited neutralization breadth and difficulty in producing large amounts of homogeneous membrane-associated E1E2 have hampered efforts to develop an E1E2-based vaccine. Our previous work described the design and biochemical validation of a native-like soluble secreted form of E1E2 (sE1E2). Here, we describe the immunogenic characterization of the sE1E2 complex. sE1E2 elicited broadly neutralizing antibodies in immunized mice, with increased neutralization breadth relative to the membrane-associated E1E2, thereby validating this platform as a promising model system for vaccine development.

28 August 2013 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Closed access
PDF file
SMShuja S. Malik
Shuja S. Malik
DPDimeka N. Patterson
Dimeka N. Patterson
ZNZiphezinhle Ncube
Ziphezinhle Ncube
ETEric Toth
Eric Toth

18 May 2024 in Viruses
Verified
Journal Article
Open access
PDF file
BPBrian G. Pierce
Brian G. Pierce
NFNathaniel Felbinger
Nathaniel Felbinger
MMMatthew Metcalf
Matthew Metcalf
ETEric Toth
Eric Toth
GOGilad Ofek
Gilad Ofek
TFThomas Fuerst
Thomas Fuerst
Hepatitis C virus (HCV) is a major medical health burden and the leading cause of chronic liver disease and cancer worldwide. More than 58 million people are chronically infected with HCV, with 1.5 million new infections occurring each year. An effective HCV vaccine is a major public health and medical need as recognized by the World Health Organization. However, due to the high variability of the virus and its ability to escape the immune response, HCV rapidly accumulates mutations, making vaccine development a formidable challenge. An effective vaccine must elicit broadly neutralizing antibodies (bnAbs) in a consistent fashion. After decades of studies from basic research through clinical development, the antigen of choice is considered the E1E2 envelope glycoprotein due to conserved, broadly neutralizing antigenic domains located in the constituent subunits of E1, E2, and the E1E2 heterodimeric complex itself. The challenge has been elicitation of robust humoral and cellular responses leading to broad virus neutralization due to the relatively low immunogenicity of this antigen. In view of this challenge, structure-based vaccine design approaches to stabilize key antigenic domains have been hampered due to the lack of E1E2 atomic-level resolution structures to guide them. Another challenge has been the development of a delivery platform in which a multivalent form of the antigen can be presented in order to elicit a more robust anti-HCV immune response. Recent nanoparticle vaccines are gaining prominence in the field due to their ability to facilitate a controlled multivalent presentation and trafficking to lymph nodes, where they can interact with both the cellular and humoral components of the immune system. This review focuses on recent advances in understanding the E1E2 heterodimeric structure to facilitate a rational design approach and the potential for development of a multivalent nanoparticle-based HCV E1E2 vaccine. Both aspects are considered important in the development of an effective HCV vaccine that can effectively address viral diversity and escape.